Cancer Stem Cells Market Expected to Reach $2.7 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Cancer Stem Cells Market," The cancer stem cells market size was $1.1 billion in 2021, and is estimated to reach $2.7 billion by 2031, growing at a CAGR of 10% from 2022 to 2031.

Cancer develops when abnormal cells in a particular area of the body divide uncontrollably. Specialized human cells known as stem cells have a number of distinguishing traits, including the ability to identify cancer cells, produce a variety of bioactive compounds, and inhibit the immune system, all of which increase tumor targeting and aid in the treatment of various types of cancer. Owing to these characteristics, cancer stem cells therapy is more effective compared to other gene therapies.  Preclinical stem cell technologies have recently demonstrated promise for use in individualized cancer treatment. The cancer stem cell-focused therapeutic gain is expected to be applied in tailored cancer stem cell therapy which is a major factor estimated to propel the cancer stem cells market size in the upcoming years.

However, the market for cancer stem cells is limited by strict healthcare agency regulations and the high cost of stem cell therapy treatments. Because stem cell therapies are generally experimental and are not usually covered by health insurance policies or government-sponsored incentives, no significant insurance companies now offer coverage for them. These factors are anticipated to restrict the cancer stem cells market advancements in the upcoming years. 

Stem cell technology has the potential to revolutionize cancer treatment. The delivery of a site-specific anti-tumor medication is made easier by stem cells migrating to solid tumors and micro metastatic lesions. In order to circumvent the short half-lives of traditional chemotherapeutic medicines, stem cells can be genetically modified to stably express a range of anticancer medications. Also, the market for cancer stem cells is expanding as a result of the quick uptake of stem cells by medical professionals for tissue regeneration and as carriers of anti-cancer drugs. Medical specialists from all over the world reported positive results in treating tumors with stem cells. These factors are anticipated to boost market growth in the upcoming years.

The global cancer stem cells market share is segmented based on cancer forms, application, and region. By cancer forms, it is classified into breast, blood, lung, brain, colorectal, pancreatic, bladder, liver, and others. By application, it is classified into targeted cancerous stem cells and stem cell-based cancer therapy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in the cancer stem cells market report include AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.

The report offers a comprehensive analysis of the global cancer stem cells market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. The report also sheds light on the present scenario and upcoming trends & developments that are contributing to the cancer stem cells market growth. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.

Impact of Covid-19 on the Global Cancer Stem Cells Market Industry

• The COVID-19 pandemic has impacted all stages of cancer treatment, including postponing cancer diagnosis and treatments and stopping clinical trials. To guarantee that patients continue to receive crucial care while reducing exposure to COVID-19 infection.
• Stem cell therapy and stem cell-derived tissue engineering models have garnered a lot of attention as a new treatment and research tool during COVID-19 pandemic.
• Social distancing norms, closed borders, and production constraints, due to the pandemic, across various countries such as China, India, and the U.S. have affected the global cancer stem cells industry.
• The ongoing COVID-19 epidemic and the subsequent lockdowns in numerous nations around the world are probably going to put pressure on the manufacturers to meet the demand for cancer cell therapies in the future.

Key Findings of the Study

• Based on cancer forms, the breast cancer sub-segment emerged as the global leader in 2021 and bladder sub-segment is anticipated to be the fastest growing sub-segment during the forecast period.
• Based on application, the stem cell-based cancer therapy sub-segment emerged as the global leader in 2021 and targeted cancerous stem cells sub-segment is predicted to show the fastest growth in the upcoming years.
• Based on region, the North America market registered the highest market share in 2021 and is projected to maintain the position during the forecast period.